Potential of GLP-1 Analogs in Managing Hyperphagia and Obesity in Prader-Willi Syndrome: A Review of Efficacy and Safety
Introduction: Prader-Willi Syndrome (PWS) is a genetic disorder marked by hyperphagia, obesity, developmental delays, and behavioral challenges. Traditional treatments like dietary control and growth hormone therapy often fail to effectively manage these symptoms. Recently, glucagon-like peptide-1 (...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Nicolaus Copernicus University in Toruń,
2024-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_a3de72d49e3e4c59b1f8861e7e96620d | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Olga Grelewicz |e author |
| 700 | 1 | 0 | |a Adam Juśkiewicz |e author |
| 700 | 1 | 0 | |a Elwira Servaas |e author |
| 700 | 1 | 0 | |a Mateusz Haber |e author |
| 700 | 1 | 0 | |a Paula Kula |e author |
| 700 | 1 | 0 | |a Alicja Kotula |e author |
| 700 | 1 | 0 | |a Adrianna Czachor |e author |
| 700 | 1 | 0 | |a Natalia Kucy |e author |
| 245 | 0 | 0 | |a Potential of GLP-1 Analogs in Managing Hyperphagia and Obesity in Prader-Willi Syndrome: A Review of Efficacy and Safety |
| 260 | |b Nicolaus Copernicus University in Toruń, |c 2024-10-01T00:00:00Z. | ||
| 500 | |a 10.12775/QS.2024.25.54915 | ||
| 500 | |a 2450-3118 | ||
| 520 | |a Introduction: Prader-Willi Syndrome (PWS) is a genetic disorder marked by hyperphagia, obesity, developmental delays, and behavioral challenges. Traditional treatments like dietary control and growth hormone therapy often fail to effectively manage these symptoms. Recently, glucagon-like peptide-1 (GLP-1) analogs have shown potential in treating PWS. This review assesses the efficacy, safety and mechanisms of GLP-1 analogs in PWS treatment. They improve glycemic control, cardiovascular health, and appetite regulation, contributing to better weight management and overall health in PWS patients. These analogs enhance insulin secretion, inhibit glucagon release, and slow gastric emptying, helping to reduce postprandial glucose spikes and caloric intake. Results: Several small-scale studies and case reports have shown mixed results regarding the effectiveness of GLP-1 analogs in reducing BMI and hyperphagia in PWS patients. Although the studies demonstrated varied outcomes in terms of BMI reduction, all of them reported improvement in satiety or appetite levels. Conclusions: Overall, GLP-1 analogs hold promise for addressing hyperphagia, obesity, and glycemic control in PWS patients, improving their overall health and quality of life. Continued research and long-term studies are essential to establish these benefits and optimize treatment strategies. | ||
| 546 | |a EN | ||
| 690 | |a Prader Willi Syndrome | ||
| 690 | |a obesity | ||
| 690 | |a hyperphagia | ||
| 690 | |a GLP agonist | ||
| 690 | |a GLP-1RA | ||
| 690 | |a Sports | ||
| 690 | |a GV557-1198.995 | ||
| 690 | |a Sports medicine | ||
| 690 | |a RC1200-1245 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Quality in Sport, Vol 25 (2024) | |
| 787 | 0 | |n https://apcz.umk.pl/QS/article/view/54915 | |
| 787 | 0 | |n https://doaj.org/toc/2450-3118 | |
| 856 | 4 | 1 | |u https://doaj.org/article/a3de72d49e3e4c59b1f8861e7e96620d |z Connect to this object online. |